Browse the corpus

In response to a recommendation by the National Asthma Education and Prevention Program (NAEPP) Coordinating Committee, an Expert Panel was convened by the National Heart, Lung, and Blood Institute (NHLBI) to update the asthma guidelines. Several measures were taken in the development of these asthma guidelines to enhance transparency of the evidence review process and to better manage any potential or perceived conflict of interest. In addition to using a methodologist to guide preparation of the Evidence Tables, several layers of external content review were also embedded into the guidelines development process. Expert Panel members and consultant reviewers completed financial disclosure forms that are summarized below. In addition to review by consultants, an early draft of the guidelines was circulated to a panel of guidelines end-users (the Guidelines Implementation Panel) appointed specifically for their review and feedback on ways to enhance guidelines utilization by primary care clinicians, health care delivery organizations, and third-party payors. Finally, a draft of the guidelines was posted on the NHLBI Web Site for review and comment by the NAEPP Coordinating Committee and to allow opportunity for public review and comment before the guidelines were finalized and released.

Agency for Healthcare Research and Quality Allergy and Asthma Network Mothers of Asthmatics American Academy of Allergy, Asthma, and Immunology Kurtis S. Elward, M.D., M.P.H., F.A.A.F.P. American Academy of Physician Assistants American Association for Respiratory Care Thomas J. Kallstrom, R.R.T., F.A.A.R.C., AE-C American College of Allergy, Asthma, and Immunology American College of Emergency Physicians Richard M. Nowak, M.D., M.B.A., F.A.C.E.P. Karen Huss, D.N.Sc., R.N., A.P.R.N.B.C., F.A.A.N., F.A.A.A.A.I. Lani S. M. Wheeler, M.D., F.A.A.P., F.A.S.H.A. American Society of Health-System Pharmacists Asthma and Allergy Foundation of America Council of State and Territorial Epidemiologists National Center for Chronic Disease Prevention, Centers for Disease Control and Prevention (CDC) National Center for Environmental Health, CDC National Center for Health Statistics, CDC National Institute for Occupational Safety and Health, CDC National Heart, Lung, and Blood Institute National Heart, Lung, and Blood Institute NIH, Ad Hoc Committee on Minority Populations National Institute of Allergy and Infectious Diseases (NIAID), NIH National Institute of Environmental Health Sciences, NIH U.S. Environmental Protection Agency Indoor Environments Division U.S. Environmental Protection Agency Office of Research and Development

Susan L. Janson, D.N.Sc., R.N., A.N.P., F.A.A.N. University of New Mexico Health Sciences Center University of Wisconsin Hospital and Clinics National Jewish Medical and Research Center University of Virginia School of Medicine National Jewish Medical and Research Center Development of the resource document and the guidelines report was funded by the NHLBI, NIH. Expert Panel members completed financial disclosure forms, and the Expert Panel members disclosed relevant financial interests to each other prior to their discussions. Expert Panel members participated as volunteers and were compensated only for travel expenses related to the Expert Panel meetings. Financial disclosure information covering the 3-year period during which the guidelines were developed is provided for each Panel member below. Dr. Busse has served on the Speakers' Bureaus of GlaxoSmithKline, Merck, Novartis, and Pfizer; and on the Advisory Boards of Altana, Centocor, Dynavax, Genentech/Novartis, GlaxoSmithKline, Isis, Merck, Pfizer, Schering, and Wyeth. He has received funding/grant support for research projects from Astellas, AstraZeneca, Centocor, Dynavax, GlaxoSmithKline, Novartis, and Wyeth. Dr. Busse also has research support from the NIH.

Dr. Boushey has served as a consultant for Altana, Protein Design Lab, and Sumitomo. He has received honoraria from (Boehringer-Ingelheim, Genentech, Merck, Novartis, and Sanofi-Aventis, and funding/grant support for research projects from the NIH. Dr. Camargo has served on the Speakers' Bureaus of AstraZeneca, GlaxoSmithKline, Merck, and Schering-Plough; and as a consultant for AstraZeneca, Critical Therapeutics, Dey Laboratories, GlaxoSmithKline, MedImmune, Merck, Norvartis, Praxair, Respironics, Schering-Plough, Sepracor, and TEVA. He has received funding/grant support for research projects from a variety of Government agencies and not-for-profit foundations, as well as AstraZeneca, Dey Laboratories, GlaxoSmithKline, MedImmune, Merck, Novartis, and Respironics. Dr. Evans has received funding/grant support for research projects from the NHLBI. Dr. Foggs has served on the Speakers' Bureaus of GlaxoSmithKline, Merck, Pfizer, Sepracor, and UCB Pharma; on the Advisory Boards of Alcon, Altana, AstraZeneca, Critical Therapeutics, Genentech, GlaxoSmithKline, and IVAX; and as consultant for Merck and Sepracor. He has received funding/grant support for research projects from GlaxoSmithKline. Dr. Janson has served on the Advisory Board of Altana, and as a consultant for Merck. She has received funding/grant support for research projects from the NHLBI.

Dr. Kelly has served on the Speakers' Bureaus of AstraZeneca and GlaxoSmithKline; and on the Advisory Boards of AstraZeneca, MAP Pharmaceuticals, Merck, Novartis, and Sepracor. Dr. Lemanske has served on the Speakers' Bureaus of GlaxoSmithKline and Merck, and as a consultant for AstraZeneca, Aventis, GlaxoSmithKline, Merck, and Novartis. He has received honoraria from Altana, and funding/grant support for research projects from the NHLBI and NIAID. Dr. Martinez has served on the Advisory Board of Merck and as a consultant for Genentech, GlaxaSmithKline, and Pfizer. He has received honoraria from Merck. Dr. Meyer has no relevant financial interests. Dr. Nelson has served on the Speakers' Bureaus of AstraZeneca, GlaxoSmithKline, Pfizer, and Schering-Plough; and as a consultant for Abbott Laboratories, Air Pharma, Altana Pharma US, Astellas, AstraZeneca, Curalogic, Dey Laboratories, Dynavax Technologies, Genentech/Novartis, GlaxoSmithKline, Inflazyme Pharmaceuticals, MediciNova, Protein Design Laboratories, Sanofi-Aventis, Schering-Plough, and Wyeth Pharmaceuticals. He has received funding/grant support for research projects from Altana, Astellas, AstraZeneca, Behringer, Critical Therapeutics, Dey Laboratories, Epigenesis, Genentech, GlaxoSmithKline, Hoffman LaRoche, IVAX, Medicinova, Novartis, Sanofi-Aventis, Schering-Plough, Sepracor, TEVA, and Wyeth.

Dr. Platts-Mills has served on the Advisory Committee of Indoor Biotechnologies. He has received funding/grant support for a research project from Pharmacia Diagnostics. Dr. Schatz has served on the Speakers' Bureaus of AstraZeneca, Genentech, GlaxoSmithKline, and Merck; and as a consultant for GlaxoSmithKline on an unbranded asthma initiative. He has received honoraria from AstraZeneca, Genentech, GlaxoSmithKline and Merck. He has received funding/grant support for research projects from GlaxoSmithKline and Merck and Sanofi-Adventis. Dr. Shapiro served on the Speakers' Bureaus of AstraZeneca, Genentech, GlaxoSmithKline, IVAX Laboratories, Key Pharmaceuticals, Merck, Pfizer Pharmaceuticals, Schering Corporation, UCB Pharma, and 3M; and as a consultant for Altana, AstraZeneca, Dey Laboratories, Genentech/Novartis, GlaxoSmithKline, ICOS, IVAX Laboratories, Merck, Sanofi-Aventis, and Sepracor. She received funding/grant support for research projects from Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers-Squibb, Dey Laboratories, Fujisawa Pharmaceuticals, Genentech, GlaxoSmithKline, Immunex, Key, Lederle, Lilly Research, MedPointe Pharmaceuticals, Medtronic Emergency Response Systems, Merck, Novartis, Pfizer, Pharmaxis, Purdue Frederick, Sanofi-Aventis, Schering, Sepracor, 3M Pharmaceuticals, UCB Pharma, and Upjohn Laboratories.

Dr. Stoloff has served on the Speakers' Bureaus of Alcon, Altana, AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Pfizer, Sanofi-Aventis, and Schering; and as a consultant for Alcon, Altana, AstraZeneca, Dey, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi-Aventis, and Schering. Dr. Szefler has served on the Advisory Boards of Altana, AstraZeneca, Genentech, GlaxoSmithKline, Merck, Novartis, and Sanofi-Aventis; and as a consultant for Altana, AstraZeneca, Genentech, GlaxoSmithKline, Merck, Novartis, and Sanofi-Aventis. He has received funding/grant support for a research project from Ross. Dr. Weiss has served on the Advisory Board of Genentech, and as a consultant for Genentech and GlaxoSmithKline. He has received funding/grant support for research projects from GlaxoSmithKline. Dr. Yawn has served on the Advisory Boards of Altana, AstraZeneca, Merck, Sanofi-Aventis, and Schering-Plough. She has received honoraria from Pfizer and Schering-Plough, and funding/grant support for research projects from the Agency for Healthcare Research and Quality, the CDC, the NHLBI, Merck, and Schering-Plough.

The Expert Panel acknowledges the following consultants for their review of an early draft of the report. Financial disclosure information covering a 12-month period prior to the review of the guidelines is provided below for each consultant. University of Pennsylvania Medical Center University of Michigan School of Public Health University of California–Los Angeles, School of Medicine Brian H. Rowe, M.D., M.Sc., C.C.F.P. (E.M.), F.C.C.P. National Jewish Medical and Research Center Dr. Apter owns stock in Johnson & Johnson. She has received funding/grant support for research projects from the NHLBI. Dr. Clark has no relevant financial interests. Dr. Fulhlbrigge has served on the Speakers' Bureau of GlaxoSmithKline, the Advisory Boards of GlaxoSmithKline and Merck, the Data Systems Monitoring Board for a clinical trial sponsored by Sepracor, and as a consultant for GlaxoSmithKline. She has received honoraria from GlaxoSmithKline and Merck, and funding/grant support for a research project from Boehringer Ingelheim. Dr. Israel has served on the Speakers' Bureau of Genentech and Merck, and as a consultant for Asthmatx, Critical Therapeutics, Genentech, Merck, Novartis Pharmaceuticals, Protein Design Labs, Schering-Plough Company, and Wyeth. He has received funding/grant support for research projects from Asthmatx, Boehringer Ingelheim, Centocor, Genentech, GlaxoSmithKline, and Merck.

Dr. Kattan has served on the Speakers' Bureau of AstraZeneca. Dr. Krishnan has received funding/grant support for a research project from Hill-Rom, Inc. Dr. Li has received funding/grant support for research projects from the American Lung Association, GlaxoSmithKline, Pharming, and ZLB Behring. Dr. Rachelefsky has served on the Speakers' Bureaus of AstraZeneca, GlaxoSmithKline, IVAX, Medpointe, Merck, and Schering-Plough. He has received honoraria from AstraZeneca, GlaxoSmithKline, IVAX, Medpointe, Merck, and Schering-Plough. Dr. Rowe has served on the Advisory Boards of Abbott, AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline. He has received honoraria from Abbott, AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline. He has received funding/grant support for research projects from Abbott, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Trudell. Dr. Sutherland has served on the Speakers' Bureau of Novartis/Genentech and the Advisory Board of Dey Laboratories. He has received honoraria from IVAX and funding/grant support for research projects from GlaxoSmithKline and the NIH.

Dr. Wilson has served as a consultant for the Department of Urology, University of California, San Francisco (UCSF); Asthmatx, Inc.; and the Stanford-UCSF Evidence-Based Practice Center. She has received funding/grant support for research projects from the NHLBI and from a subcontract to Stanford University from Blue Shield Foundation. Dr. Wood has served on the Speakers' Bureaus of Dey Laboratories, GlaxoSmithKline, and Merck; on the Advisory Board of Dey Laboratories; and as a consultant to Dey Laboratories. He has received honoraria from Dey Laboratories, GlaxoSmithKline, and Merck, and funding/grant support for a research project from Genentech. Dr. Zeiger has served on the Data Monitoring Board of Genentech, Advisory Board of GlaxoSmithKline, and as a consultant for Aerocrine, AstraZeneca, and Genentech. He has received honoraria from AstraZeneca and funding/grant support for a research project from Sanofi-Aventis.

Chief, Enhanced Dissemination and Utilization Branch Division for the Application of Research Discoveries Associate Director for Prevention, Education, and Control Division for the Application of Research Discoveries National Asthma Education and Prevention Program Division for the Application of Research Discoveries